AM Best withdraws ratings of Elevance Health's Hawaii captive

AM Best withdrew the ratings of WellPoint Insurance Services, a captive of Elevance Health, at the company's request. The ratings were affirmed as 'A- (Excellent)' with a 'stable' outlook, reflecting adequate balance sheet strength, operating performance, and risk management. Elevance Health's financial strength supports the captive, with planned capital growth and no dividends to the parent.

Original reporting
Published Sep 24, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AM Best withdraws ratings of Elevance Health's Hawaii captive — source image
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

The withdrawal signals a change in transparency but does not alter Elevance's overall credit profile.

02

Market read

The event is a niche corporate action with limited impact on Elevance Health's stock and the broader market.

03

What to watch

Elevance's robust parent support and existing credit facilities may offset any negative perception from the rating change.

Relevance 4/10Novelty 5/10Timing: today

Background

Elevance Health requested AM Best to withdraw the ratings of its captive insurer, indicating a shift in how the captive will be evaluated.

Company-level read

Ticker impact

$ELVNeutralMedium confidence
Context

AM Best withdrew the credit ratings of Elevance Health's Hawaii captive, WellPoint Insurance Services, at the company's request.

Expected impact

Minimal short-term price movement for ELV; potential slight downside if investors view captive risk negatively.

Evidence & confidence

The captive is a small, non‑listed entity; Elevance retains ample capital support, limiting material effect on the parent’s stock.

Market effects

Limited impact on the health insurance sector; rating agencies may scrutinize captive structures more closely.

Minor relevance for Hawaii‑based captive insurance market.

Low global relevance; primarily a niche corporate rating event.

Counterpoint

Investors could view the rating withdrawal as a strategic move to reduce regulatory oversight, potentially freeing capital for growth.

Key entities

  • Elevance Health

    Parent health insurer (ticker ELV) that owns the captive.

  • WellPoint Insurance Services, Inc.

    Hawaii‑domiciled captive of Elevance Health.

  • AM Best

    Provider of the withdrawn credit ratings.

Related articles

$ELVHighAI 8/10

Why is Elevance Health stock surging today?

Elevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.

$ELVMedAI 8/10

Elevance holds loss ratio guidance above 90% as fall renewals near

Elevance Health reaffirmed its 2026 benefit expense ratio guidance at 90.2% (+/- 0.5%), indicating stable medical utilization and specialty pharmacy costs. The company expects to meet its adjusted earnings guidance of at least $27 per diluted share. Q2 2026 results showed an 89.7% ratio, up 0.8% YoY, driven by government business costs. Elevance, the second-largest US health insurer, processes pharmacy claims through Carelon. Steady ratio signals heavy claims payouts, impacting fall renewals.

$ELVHighAI 8/10

Elevance Health reaffirms 2026 earnings and benefit expense guidance

Elevance Health (ELV) reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share, including $6.90 in net unfavorable items, and adjusted earnings of at least $27.00 per share. The company also confirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This follows strong Q2 2026 results, with adjusted earnings of $7.45 per share and revenue of $49.8 billion, but shares faced pressure due to Medicaid concerns. Analysts have mixed price targets and ra